Everdexâ 1 Mg. 1 mg Film-coated Tablets
PDF Leaflet Revision Date: 22 January 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of early and advanced breast cancer in postmenopausal women.
Dosage (summary)
1 mg orally once daily for adults, no change for mild/moderate renal or hepatic impairment.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Tamoxifen
- Oestrogen-containing therapies
Contraindications
- Hypersensitivity
- Pre-menopausal women
- Severe renal impairment
- Moderate/severe hepatic disease
Common side effects
- Headache
- Hot flushes
- Nausea
- Rash
- Arthralgia
- Asthenia
Counselling Points
- Monitor for signs of bone health issues.
- Report any unusual bleeding.
- Caution advised when driving if experiencing somnolence.
Serious warnings
- May reduce bone mineral density, increasing fracture risk.
- Not recommended for pre-menopausal women or children.
Important Disclaimer
The Everdexâ 1 Mg. 1 mg Film-coated Tablets professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
